Karyopharm officer sells 19 shares at $2.02

Karyopharm’s chief accounting officer reported a small, non-discretionary sale of shares to cover tax withholding tied to vesting equity awards.

Rhea-AI Filing Summary

Karyopharm Therapeutics Inc. (KPTI) disclosed that Chief Accounting Officer Kristin Abate sold 19 shares of common stock on September 1, 2026 at $2.02 per share. According to the disclosure, this broker-assisted sale was made under a durable automatic sale instruction plan to satisfy withholding tax liability from vesting restricted stock units and is described as non-discretionary. After the sale, Abate directly held 23,782 shares of Karyopharm common stock.

Insider Trade Summary

Net Seller: 19 shares

Net Sell 1 txn

Insider Abate Kristin

Role Chief Accounting Officer

Sold 19 shs ($38.38)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	19	$2.02	$38.38

Holdings After Transaction: Common Stock — 23,782 shares (Direct)

Footnotes (1)

1. F1. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

Key Figures

Shares sold: 19 shares Sale price per share: $2.02 per share Shares held after transaction: 23,782 shares +1 more

4 metrics

Shares sold 19 shares Common stock sold on September 1, 2026 by the Chief Accounting Officer

Sale price per share $2.02 per share Price for the 19 Karyopharm common shares sold on September 1, 2026

Shares held after transaction 23,782 shares Direct ownership by the insider following the reported sale

Net shares sold 19 shares Net change in buy/sell activity reported in this Form 4

Key Terms

durable automatic sale instruction plan, withholding tax liability, restricted stock units, broker-assisted sale

4 terms

durable automatic sale instruction plan financial

"This transaction was effected pursuant to a durable automatic sale instruction plan"

withholding tax liability financial

"to satisfy the payment of withholding tax liability incurred upon the vesting"

restricted stock units financial

"withholding tax liability incurred upon the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

broker-assisted sale financial

"represents a broker-assisted sale of shares to satisfy the payment"

FAQ

Who is the insider involved in the latest Form 4 for KPTI?

The filing reports a transaction by Kristin Abate, who serves as Chief Accounting Officer of Karyopharm Therapeutics Inc.

What transaction did the KPTI insider report on September 1, 2026?

The insider reported a sale of 19 shares of Karyopharm common stock on September 1, 2026, described as a broker-assisted sale to cover withholding tax liability from vesting restricted stock units.

At what price were the KPTI shares sold in this Form 4 transaction?

The 19 shares of Karyopharm common stock were sold at a price of $2.02 per share, according to the disclosure.

How many KPTI shares does the insider hold after this reported sale?

After the reported sale, the insider directly holds 23,782 shares of Karyopharm Therapeutics Inc. common stock.

Was the KPTI insider sale a discretionary trade?

No. The sale is described as made under a durable automatic sale instruction plan and as a non-discretionary transaction executed to satisfy tax withholding obligations.

Did the KPTI Form 4 indicate any Rule 10b5-1 trading plan box as checked?

The document-level Rule 10b5-1 checkbox is not checked, while the footnote states the sale followed a durable automatic sale instruction plan adopted on May 27, 2021.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:58 PM Accepted by SEC EDGAR 09/02/2026 - 04:57 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Abate Kristin

(Last) (First) (Middle)

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE

(Street)

NEWTON MASSACHUSETTS 02459

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/01/2026		S(1)		19	D	$2.02	23,782	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

	/s/ Nancy Smith as Attorney-in-Fact for Kristin Abate	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)